Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Adenoviral vectors transduce alveolar macrophages in lung cancer models.

Tippimanchai DD, Nolan K, Poczobutt J, Verzosa G, Li H, Scarborough H, Huang J, Young C, DeGregori J, Nemenoff RA, Malkoski SP.

Oncoimmunology. 2018 Mar 6;7(6):e1438105. doi: 10.1080/2162402X.2018.1438105. eCollection 2018.

2.

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer.

Pilling AB, Kim J, Estrada-Bernal A, Zhou Q, Le AT, Singleton KR, Heasley LE, Tan AC, DeGregori J, Doebele RC.

Oncotarget. 2018 Jan 16;9(10):8823-8835. doi: 10.18632/oncotarget.24260. eCollection 2018 Feb 6.

3.

Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.

Gregory MA, Nemkov T, Reisz JA, Zaberezhnyy V, Hansen KC, D'Alessandro A, DeGregori J.

Exp Hematol. 2018 Feb;58:52-58. doi: 10.1016/j.exphem.2017.09.007. Epub 2017 Sep 22.

PMID:
28947392
4.

Folate dietary insufficiency and folic acid supplementation similarly impair metabolism and compromise hematopoiesis.

Henry CJ, Nemkov T, Casás-Selves M, Bilousova G, Zaberezhnyy V, Higa KC, Serkova NJ, Hansen KC, D'Alessandro A, DeGregori J.

Haematologica. 2017 Dec;102(12):1985-1994. doi: 10.3324/haematol.2017.171074. Epub 2017 Sep 7.

5.

Connecting Cancer to Its Causes Requires Incorporation of Effects on Tissue Microenvironments.

DeGregori J.

Cancer Res. 2017 Nov 15;77(22):6065-6068. doi: 10.1158/0008-5472.CAN-17-1207. Epub 2017 Jul 28.

PMID:
28754675
6.

The evolution of lifespan and age-dependent cancer risk.

Rozhok AI, DeGregori J.

Trends Cancer. 2016 Oct;2(10):552-560. doi: 10.1016/j.trecan.2016.09.004.

7.

Changing mutational and adaptive landscapes and the genesis of cancer.

Liggett LA, DeGregori J.

Biochim Biophys Acta. 2017 Apr;1867(2):84-94. doi: 10.1016/j.bbcan.2017.01.005. Epub 2017 Feb 4. Review.

8.

Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors.

Zhang G, Scarborough H, Kim J, Rozhok AI, Chen YA, Zhang X, Song L, Bai Y, Fang B, Liu RZ, Koomen J, Tan AC, Degregori J, Haura EB.

Sci Signal. 2016 Oct 18;9(450):rs12.

9.

ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.

Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, DeGregori J.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6669-E6678. Epub 2016 Oct 10.

10.

AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.

Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J.

Clin Cancer Res. 2017 Mar 15;23(6):1531-1541. doi: 10.1158/1078-0432.CCR-16-1179. Epub 2016 Sep 23.

11.

Trisomy 21 consistently activates the interferon response.

Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, Smith KP, Liggett LA, Gomez EB, Galbraith MD, DeGregori J, Espinosa JM.

Elife. 2016 Jul 29;5. pii: e16220. doi: 10.7554/eLife.16220.

12.

Deficiency of mitochondrial modulator MCJ promotes chemoresistance in breast cancer.

Fernández-Cabezudo MJ, Faour I, Jones K, Champagne DP, Jaloudi MA, Mohamed YA, Bashir G, Almarzooqi S, Albawardi A, Hashim MJ, Roberts TS, El-Salhat H, El-Taji H, Kassis A, O'Sullivan DE, Christensen BC, DeGregori J, Al-Ramadi BK, Rincon M.

JCI Insight. 2016 May 19;1(7). pii: e86873.

13.

The landscape of somatic mutations in protein coding genes in apparently benign human tissues carries signatures of relaxed purifying selection.

Yadav VK, DeGregori J, De S.

Nucleic Acids Res. 2016 Mar 18;44(5):2075-84. doi: 10.1093/nar/gkw086. Epub 2016 Feb 15.

14.

Stochastic modeling reveals an evolutionary mechanism underlying elevated rates of childhood leukemia.

Rozhok AI, Salstrom JL, DeGregori J.

Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):1050-5. doi: 10.1073/pnas.1509333113. Epub 2016 Jan 11.

15.

Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors.

Henry CJ, Casás-Selves M, Kim J, Zaberezhnyy V, Aghili L, Daniel AE, Jimenez L, Azam T, McNamee EN, Clambey ET, Klawitter J, Serkova NJ, Tan AC, Dinarello CA, DeGregori J.

J Clin Invest. 2015 Dec;125(12):4666-80. doi: 10.1172/JCI83024. Epub 2015 Nov 9.

16.

Evolved Cellular Mechanisms to Respond to Genotoxic Insults: Implications for Radiation-Induced Hematologic Malignancies.

Fleenor CJ, Higa K, Weil MM, DeGregori J.

Radiat Res. 2015 Oct;184(4):341-51. doi: 10.1667/RR14147.1. Epub 2015 Sep 28. Review.

17.

Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations.

Rozhok AI, DeGregori J.

Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):8914-21. doi: 10.1073/pnas.1501713112.

18.

A Critical Examination of the "Bad Luck" Explanation of Cancer Risk.

Rozhok AI, Wahl GM, DeGregori J.

Cancer Prev Res (Phila). 2015 Sep;8(9):762-4. doi: 10.1158/1940-6207.CAPR-15-0229. Epub 2015 Jun 29.

19.

Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma.

Henry CJ, Sedjo RL, Rozhok A, Salstrom J, Ahnen D, Levin TR, D'Agostino R Jr, Haffner S, DeGregori J, Byers T.

BMC Cancer. 2015 Mar 14;15:123. doi: 10.1186/s12885-015-1115-2.

20.

Oncogenic drivers and mitochondrial dependency.

Alvarez-Calderon F, DeGregori J.

Aging (Albany NY). 2015 Mar;7(3):148-9. No abstract available.

21.

PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer.

Avasarala S, Van Scoyk M, Karuppusamy Rathinam MK, Zerayesus S, Zhao X, Zhang W, Pergande MR, Borgia JA, DeGregori J, Port JD, Winn RA, Bikkavilli RK.

J Biol Chem. 2015 May 22;290(21):13479-89. doi: 10.1074/jbc.M114.636050. Epub 2015 Apr 6.

22.
23.

Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.

Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, DeGregori J.

Clin Cancer Res. 2015 Mar 15;21(6):1360-72. doi: 10.1158/1078-0432.CCR-14-2146. Epub 2014 Dec 29.

24.

Personalized one-two punches for lung cancer.

Scarborough HA, Bunn PA Jr, DeGregori J.

Cell Res. 2015 Mar;25(3):269-70. doi: 10.1038/cr.2014.168. Epub 2014 Dec 30.

25.

Contrasting roles for C/EBPα and Notch in irradiation-induced multipotent hematopoietic progenitor cell defects.

Fleenor CJ, Rozhok AI, Zaberezhnyy V, Mathew D, Kim J, Tan AC, Bernstein ID, DeGregori J.

Stem Cells. 2015 Apr;33(4):1345-58. doi: 10.1002/stem.1936.

26.

Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.

Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, Pollyea DA, Takebe N, Christians U, Gore L, DeGregori J, Porter CC.

Am J Hematol. 2014 Sep;89(9):896-903. doi: 10.1002/ajh.23776. Epub 2014 Jun 19.

27.

Patterns of somatically acquired amplifications and deletions in apparently normal tissues of ovarian cancer patients.

Aghili L, Foo J, DeGregori J, De S.

Cell Rep. 2014 May 22;7(4):1310-9. doi: 10.1016/j.celrep.2014.03.071. Epub 2014 May 1.

28.

Cancer evolution is associated with pervasive positive selection on globally expressed genes.

Ostrow SL, Barshir R, DeGregori J, Yeger-Lotem E, Hershberg R.

PLoS Genet. 2014 Mar 6;10(3):e1004239. doi: 10.1371/journal.pgen.1004239. eCollection 2014 Mar.

29.

Inhibiting tyrosine phosphorylation of protein kinase Cδ (PKCδ) protects the salivary gland from radiation damage.

Wie SM, Adwan TS, DeGregori J, Anderson SM, Reyland ME.

J Biol Chem. 2014 Apr 11;289(15):10900-8. doi: 10.1074/jbc.M114.551366. Epub 2014 Feb 25.

30.

Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia.

Yang X, La Rosa FG, Genova EE, Huber K, Schaack J, Degregori J, Serkova NJ, Li Y, Su LJ, Kessler E, Flaig TW.

PLoS One. 2013 Sep 18;8(9):e74809. doi: 10.1371/journal.pone.0074809. eCollection 2013.

31.

Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.

Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, Degregori JV, Messersmith WA, Winn RA, Eckhardt SG.

Clin Cancer Res. 2013 Aug 1;19(15):4149-62. doi: 10.1158/1078-0432.CCR-12-3140. Epub 2013 Jun 11.

32.
33.

Targeting developmental pathways in children with cancer: what price success?

Gore L, DeGregori J, Porter CC.

Lancet Oncol. 2013 Feb;14(2):e70-8. doi: 10.1016/S1470-2045(12)70530-2. Review.

34.

Using functional genomics to overcome therapeutic resistance in hematological malignancies.

Alvarez-Calderon F, Gregory MA, DeGregori J.

Immunol Res. 2013 Mar;55(1-3):100-15. doi: 10.1007/s12026-012-8353-z. Review.

35.

Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age?

DeGregori J.

Oncogene. 2013 Apr 11;32(15):1869-75. doi: 10.1038/onc.2012.281. Epub 2012 Jul 2. Review.

36.

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

Casás-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA Jr, Chan DC, Tan AC, DeGregori J.

Cancer Res. 2012 Aug 15;72(16):4154-64. doi: 10.1158/0008-5472.CAN-11-2848. Epub 2012 Jun 27.

37.

ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.

Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM.

Nat Chem Biol. 2012 Jul;8(7):646-54. doi: 10.1038/nchembio.965. Epub 2012 Jun 3.

38.

Extracellular cyclophilin-A stimulates ERK1/2 phosphorylation in a cell-dependent manner but broadly stimulates nuclear factor kappa B.

Bahmed K, Henry C, Holliday M, Redzic J, Ciobanu M, Zhang F, Weekes C, Sclafani R, Degregori J, Eisenmesser E.

Cancer Cell Int. 2012 Jul 4;12(1):19. doi: 10.1186/1475-2867-12-19.

39.

Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.

Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, Zaberezhnyy V, Patel PR, Gao D, Tan AC, DeGregori J.

Leukemia. 2012 Jun;26(6):1266-76. doi: 10.1038/leu.2011.392. Epub 2012 Jan 13.

40.

How cancer shapes evolution, and how evolution shapes cancer.

Casás-Selves M, Degregori J.

Evolution (N Y). 2011 Dec;4(4):624-634.

41.

Aging-associated changes in hematopoiesis and leukemogenesis: what's the connection?

Henry CJ, Marusyk A, DeGregori J.

Aging (Albany NY). 2011 Jun;3(6):643-56. Review.

42.

Evolved tumor suppression: why are we so good at not getting cancer?

DeGregori J.

Cancer Res. 2011 Jun 1;71(11):3739-44. doi: 10.1158/0008-5472.CAN-11-0342. Epub 2011 May 24.

43.

A new role for E2F1 in DNA repair: all for the greater good.

Degregori J.

Cell Cycle. 2011 Jun 1;10(11):1716. Epub 2011 Jun 1. No abstract available.

44.

Relative fitness of hematopoietic progenitors influences leukemia progression.

Porter CC, Baturin D, Choudhary R, DeGregori J.

Leukemia. 2011 May;25(5):891-5. doi: 10.1038/leu.2011.22. Epub 2011 Feb 18. No abstract available.

45.

Strong foreign promoters contribute to innate inflammatory responses induced by adenovirus transducing vectors.

Schaack J, Bennett ML, Shapiro GS, DeGregori J, McManaman JL, Moorhead JW.

Virology. 2011 Mar 30;412(1):28-35. doi: 10.1016/j.virol.2010.12.054. Epub 2011 Jan 20.

46.

Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis.

Henry CJ, Marusyk A, Zaberezhnyy V, Adane B, DeGregori J.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21713-8. doi: 10.1073/pnas.1005486107. Epub 2010 Nov 22.

47.

Ionizing radiation and hematopoietic malignancies: altering the adaptive landscape.

Fleenor CJ, Marusyk A, DeGregori J.

Cell Cycle. 2010 Aug 1;9(15):3005-11. Epub 2010 Aug 7.

48.

Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.

Bui MR, Hodson V, King T, Leopold D, Dai S, Fiolkoski V, Oakes S, Duke R, Apelian D, Franzusoff A, DeGregori J.

Vaccine. 2010 Aug 23;28(37):6028-35. doi: 10.1016/j.vaccine.2010.06.085. Epub 2010 Jul 7.

49.

Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.

Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J.

Cancer Cell. 2010 Jul 13;18(1):74-87. doi: 10.1016/j.ccr.2010.04.025.

50.

Ionizing radiation-induced long-term expression of senescence markers in mice is independent of p53 and immune status.

Le ON, Rodier F, Fontaine F, Coppe JP, Campisi J, DeGregori J, Laverdière C, Kokta V, Haddad E, Beauséjour CM.

Aging Cell. 2010 Jun;9(3):398-409. doi: 10.1111/j.1474-9726.2010.00567.x. Epub 2010 Mar 13.

Supplemental Content

Loading ...
Support Center